Ocular Therapeutix公司 OCUL 深 沪
等待开盘 08-21 09:30:00 美东时间
11.96
-0.180
-1.48%
华盛通- 最 高12.34
- 今 开12.10
- 成交量 212.27万股
- 最 低 11.68
- 昨 收 12.14
- 总市值 19.02亿
- 52周最高 12.91
- 市盈率 静 --
- 换手率 1.34%
- 52周最低 5.785
- 委 比 -31.03%
- 总股本 1.59亿
- 历史最高 44.19
- 量 比 1.09
- 振 幅 5.44%
- 历史最低 1.995
- 每 手 1
- 风险率 2.47%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Ocular Therapeutix™ Receives FDA Agreement Under Special Protocol Assessment (SPA) for Registrational Trial of AXPAXLI™ in NPDR
Ocular Therapeutix received FDA agreement on a Special Protocol Assessment (SPA) for its planned clinical trial of AXPAXLI for non-proliferative diabetic retinopathy (NPDR). The company plans to outline its clinical trial design, timing, and development strategy for NPDR and diabetic macular edema (DME) at its Investor Day on September 30, 2025. AXPAXLI showed promising results in early trials, with no disease progression in NPDR patients and imp...
08-12 11:00
Oculis to Participate in Upcoming H.C Wainwright 5th Annual Ophthalmology Virtual Conference
Oculis Holding AG will participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference on August 13, 2025. Sylvia Cheung, CFO, will present a corporate update available via webcast at 7:00am ET. Snehal Shah, President of R&D, will join a panel discussion on Retinal Disorders from 11:00am to 12:00pm ET. Both sessions will be accessible via webcast and links will be posted on the Events & Presentation page under the Investors & Media...
08-12 08:00
美股大行评级 | Rivian遭多家大行下调目标价；巴克莱上调超微公司目标价从130美元升至200美元
今日重点评级关注：韦德布什：维持Gossamer Bio"跑赢大市"评级，目标价从4美元升至5美元；HC Wainwright & Co.：维持EyePoint Pharmaceuticals"买入"评级，目标价从22美元升至23美元
08-07 09:46
Ocular Therapeutix shares are trading lower after the company reported a Q2 EPS miss.
Ocular Therapeutix shares are trading lower after the company reported a Q2 EPS...
08-05 21:07
Earnings Scheduled For August 5, 2025
Companies Reporting Before The Bell • Silicon Laboratories (NASDAQ:SLAB) is exp...
08-05 16:32
What's Next: Ocular Therapeutix's Earnings Preview
Ocular Therapeutix (NASDAQ:OCUL) will release its quarterly earnings report on ...
08-05 04:04
Ocular Therapeutix™ to Report Second Quarter 2025 Financial Results on August 5, 2025
Ocular Therapeutix, Inc. announced it will host a conference call and webcast on August 5, 2025, at 8:00 AM ET to discuss Q2 2025 business progress and financial results. The call-in numbers are 1-877-407-9039 (U.S.) and 1-201-689-8470 (International), with webcast access available via the provided link or the company’s website. The webcast will be available for replay for at least 30 days. The company, dedicated to redefining retinal care, is ad...
07-29 11:00
Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences
Ocular Therapeutix, Inc. will participate in scientific conferences in July and August 2025, including the 8th OIS Retina Innovation Summit, ASRS 2025 Annual Meeting, and WIO 2025. Presentations and posters will focus on drug delivery innovations and clinical trials for RETINA disease treatments, such as axitinib hydrogel (OTX-TKI). The company emphasizes its ELUTYX™ hydrogel technology, with AXPAXLI™ in Phase 3 trials for wet AMD. Investors and ...
07-22 11:00
Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company
Ocular Therapeutix, Inc. has unveiled its new corporate branding and website, reflecting its commitment to redefining the retina experience and addressing the challenges of retinal diseases like wet age-related macular degeneration (AMD). The rebranded logo, designed with visual accessibility and scientific innovation, symbolizes the eye and retina with vibrant colors representing human vision. The company's investigational therapy, AXPAXLI™, aim...
06-26 17:54
Carnival Posts Better-Than-Expected Earnings, Joins Liminatus Pharma, Coinbase Global, Uber And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were higher, with the Dow Jones index gaining around 450 points on ...
06-25 00:30
